These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 10741710)
1. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710 [TBL] [Abstract][Full Text] [Related]
2. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403 [TBL] [Abstract][Full Text] [Related]
3. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144 [TBL] [Abstract][Full Text] [Related]
4. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446 [TBL] [Abstract][Full Text] [Related]
5. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin. Chapman PB; Morrisey D; Panageas KS; Williams L; Lewis JJ; Israel RJ; Hamilton WB; Livingston PO Clin Cancer Res; 2000 Dec; 6(12):4658-62. PubMed ID: 11156217 [TBL] [Abstract][Full Text] [Related]
6. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Kitamura K; Livingston PO; Fortunato SR; Stockert E; Helling F; Ritter G; Oettgen HF; Old LJ Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2805-9. PubMed ID: 7708728 [TBL] [Abstract][Full Text] [Related]
7. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Livingston P; Zhang S; Adluri S; Yao TJ; Graeber L; Ragupathi G; Helling F; Fleisher M Cancer Immunol Immunother; 1997 Jan; 43(6):324-30. PubMed ID: 9067403 [TBL] [Abstract][Full Text] [Related]
8. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001 [TBL] [Abstract][Full Text] [Related]
9. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545 [TBL] [Abstract][Full Text] [Related]
10. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Dickler MN; Ragupathi G; Liu NX; Musselli C; Martino DJ; Miller VA; Kris MG; Brezicka FT; Livingston PO; Grant SC Clin Cancer Res; 1999 Oct; 5(10):2773-9. PubMed ID: 10537341 [TBL] [Abstract][Full Text] [Related]
12. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887 [TBL] [Abstract][Full Text] [Related]
13. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. Kirkwood JM; Ibrahim JG; Sosman JA; Sondak VK; Agarwala SS; Ernstoff MS; Rao U J Clin Oncol; 2001 May; 19(9):2370-80. PubMed ID: 11331315 [TBL] [Abstract][Full Text] [Related]
14. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Chapman PB; Williams L; Salibi N; Hwu WJ; Krown SE; Livingston PO Vaccine; 2004 Jul; 22(21-22):2904-9. PubMed ID: 15246627 [TBL] [Abstract][Full Text] [Related]
15. Ganglioside vaccines with emphasis on GM2. Livingston P Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678 [TBL] [Abstract][Full Text] [Related]
16. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. McCaffery M; Yao TJ; Williams L; Livingston PO; Houghton AN; Chapman PB Clin Cancer Res; 1996 Apr; 2(4):679-86. PubMed ID: 9816218 [TBL] [Abstract][Full Text] [Related]
17. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Yao TJ; Meyers M; Livingston PO; Houghton AN; Chapman PB Clin Cancer Res; 1999 Jan; 5(1):77-81. PubMed ID: 9918205 [TBL] [Abstract][Full Text] [Related]
18. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361 [TBL] [Abstract][Full Text] [Related]